|
1
|
Thygesen K, Alpert JS, Jaffe AS, Simoons
ML, Chaitman BR, White HD, Thygesen K, Alpert JS, White HD, Jaffe
AS, et al: Joint ESC/ACCF/AHA/WHF Task Force for Universal
Definition of Myocardial Infarction; Authors/Task Force Members
Chairpersons; Biomarker Subcommittee; ECG Subcommittee; Imaging
Subcommittee; Classification Subcommittee; Intervention
Subcommittee; Trials & Registries Subcommittee; Trials &
Registries Subcommittee; Trials & Registries Subcommittee;
Trials & Registries Subcommittee; ESC Committee for Practice
Guidelines (CPG); Document Reviewers: Third universal definition of
myocardial infarction. J Am Coll Cardiol. 60:1581–1598. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Braunwald E, Antman EM, Beasley JW, Califf
RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J,
Levin TN, et al: ACC/AHA guidelines for the management of patients
with unstable angina and non-ST-segment elevation myocardial
infarction. A report of the American College of Cardiology/American
Heart Association Task Force on Practice Guidelines (Committee on
the Management of Patients with Unstable Angina). J Am Coll
Cardiol. 36:970–1062. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zamani P, Schwartz GG, Olsson AG, Rifai N,
Bao W, Libby P, Ganz P and Kinlay S: Myocardial Ischemia Reduction
with Aggressive Cholesterol Lowering (MIRACL) Study Investigators:
Inflammatory biomarkers, death, and recurrent nonfatal coronary
events after an acute coronary syndrome in the MIRACL study. J Am
Heart Assoc. 2:e0031032013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Abdelmouttaleb I, Danchin N, Ilardo C,
Aimone-Gastin I, Angioï M, Lozniewski A, Loubinoux J, Le Faou A and
Guéant JL: C-Reactive protein and coronary artery disease:
additional evidence of the implication of an inflammatory process
in acute coronary syndromes. Am Heart J. 137:346–351. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhao XJ, Liu XL, He GX and Xu HP: Effects
of single-dose atorvastatin on interleukin-6, interferon gamma, and
myocardial no-reflow in a rabbit model of acute myocardial
infarction and reperfusion. Braz J Med Biol Res. 47:245–251. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhao B, Li J, Luo X, Zhou Q, Chen H and
Shi H: The role of von Willebrand factor and ADAMTS13 in the
no-reflow phenomenon: After primary percutaneous coronary
intervention. Tex Heart Inst J. 38:516–522. 2011.PubMed/NCBI
|
|
7
|
Zhou SS, Tian F, Chen YD, Wang J, Sun ZJ,
Guo J and Jin QH: Combination therapy reduces the incidence of
no-reflow after primary per-cutaneous coronary intervention in
patients with ST-segment elevation acute myocardial infarction. J
Geriatr Cardiol. 12:135–142. 2015.PubMed/NCBI
|
|
8
|
Jones PH, Davidson MH, Stein EA, Bays HE,
McKenney JM, Miller E, Cain VA and Blasetto JW: STELLAR Study
Group: Comparison of the efficacy and safety of rosuvastatin versus
atorvastatin, simvastatin, and pravastatin across doses
(STELLAR* Trial). Am J Cardiol. 92:152–160. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang JW, Chen YD, Wang CH, Yang XC, Zhu XL
and Zhou ZQ: Development and validation of a clinical risk score
predicting the no-reflow phenomenon in patients treated with
primary percutaneous coronary intervention for ST-segment elevation
myocardial infarction. Cardiology. 124:153–160. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhou H, He XY, Zhuang SW, Wang J, Lai Y,
Qi WG, Yao YA and Liu XB: Clinical and procedural predictors of
no-reflow in patients with acute myocardial infarction after
primary percutaneous coronary intervention. World J Emerg Med.
5:96–102. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Qi K, Li L, Li X, Zhao J, Wang Y, You S,
Hu F, Zhang H, Cheng Y, Kang S, et al: Cardiac microvascular
barrier function mediates the protection of Tongxinluo against
myocardial ischemia/reperfusion injury. PLoS One. 10:e01198462015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Uitterdijk A, Yetgin T, te Lintel Hekkert
M, Sneep S, Krabbendam-Peters I, van Beusekom HM, Fischer TM,
Cornelussen RN, Manintveld OC, Merkus D, et al: Vagal nerve
stimulation started just prior to reperfusion limits infarct size
and no-reflow. Basic Res Cardiol. 110:512015. View Article : Google Scholar
|
|
13
|
Ahn SJ, Park KH, Ryoo NK, Hong JH, Jung C,
Yoon CH, Han MK and Woo SJ: No-reflow phenomenon in central retinal
artery occlusion: incidence, risk factors, and clinical
implications. PLoS One. 10:e01428522015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shen Y, Wu H, Wang C, Shao H, Huang H,
Jing H and Li D: Simvastatin attenuates cardiopulmonary
bypass-induced myocardial inflammatory injury in rats by activating
peroxisome proliferator-activated receptor γ. Eur J Pharmacol.
649:255–262. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Stumpf C, Petzi S, Seybold K, Wasmeier G,
Arnold M, Raaz D, Yilmaz A, Daniel WG and Garlichs CD: Atorvastatin
enhances interleukin-10 levels and improves cardiac function in
rats after acute myocardial infarction. Clin Sci (Lond). 116:45–52.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Małek LA, Śpiewak M, Kłopotowski M, Miśko
J, Rużyłło W and Witkowski A: The size does not matter - the
presence of microvascular obstruction but not its extent
corresponds to larger infarct size in reperfused STEMI. Eur J
Radiol. 81:2839–2843. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Maksimenko AV and Turashev AD: No-reflow
phenomenon and endothelial glycocalyx of microcirculation. Biochem
Res Int. 2012:8592312012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang CH, Chen YD, Yang XC, Wang LF, Wang
HS, Sun ZJ and Liu HB: A no-reflow prediction model in patients
with ST-elevation acute myocardial infarction and primary
drug-eluting stenting. Scand Cardiovasc J. 45:98–104. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee MG, Jeong MH, Ahn Y, Cho JG, Park JC,
Kang JC, Chae SC, Hur SH, Hong TJ, Kim YJ, et al: Korea Acute
Myocardial Infarction Registry Investigators: Comparison of
paclitaxel-, sirolimus-, and zotarolimus-eluting stents in patients
with acute ST-segment elevation myocardial infarction and metabolic
syndrome. Circ J. 75:2120–2127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Choi YH, Suh SH, Choi JS, Kim CS, Sim DS,
Bae EH, Lim SY, Ma SK, Jeong MH and Kim SW: Korea Acute Myocardial
Infarction Registry Investigators: Triple vs. dual antiplatelet
therapy in patients with acute myocardial infarction and renal
dysfunction. Circ J. 76:2405–2411. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Di Sciascio G, Patti G, Pasceri V,
Gaspardone A, Colonna G and Montinaro A: Efficacy of atorvastatin
reload in patients on chronic statin therapy undergoing
percutaneous coronary intervention: Results of the ARMYDA-RECAPTURE
(Atorvastatin for Reduction of Myocardial Damage During
Angioplasty) Randomized Trial. J Am Coll Cardiol. 54:558–565. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Naing K Aung, Li L, Su Q and Wu T:
Adenosine and verapamil for no-reflow during primary percutaneous
coronary intervention in people with acute myocardial infarction.
Cochrane Database Syst Rev. 6:CD0095032013.
|
|
23
|
Blanco-Colio LM, Villa A, Ortego M,
Hernandez-Presa MA, Pascual A, Plaza JJ and Egido J:
3-Hydroxy-3-methyl-glutaryl coenzyme a reductase inhibitors,
atorvastatin and simvastatin, induce apoptosis of vascular smooth
muscle cells by downregulation of Bcl-2 expression and Rho a
prenylation. Atherosclerosis. 161:17–26. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Clearfield M: Efficacy of atorvastatin
reload in patients on chronic statin therapy undergoing
percutaneous coronary intervention. Curr Atheroscler Rep. 12:8–10.
2010. View Article : Google Scholar : PubMed/NCBI
|
